SCHEMBL6091636

SCHEMBL6091636

O=C1CCN2c3c1cccc3C(=O)NC2c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.40
PARP2 Q9UGN5 1/20 0.40
ESR1 P03372 2/20 0.39
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HTR2C P28335 4/20 0.34
HTR2B P41595 4/20 0.34
CHRM5 P08912 2/20 0.34
CHRM3 P20309 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ATM Q13315 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP3 Q9Y6F1 1/20 0.33
HTR2A P28223 2/20 0.32
SLC6A9 P48067 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089877 0.86 PARP1 (0.39) PARP1ESR1MEN1KMT2AALDH1A1
SCHEMBL6090276 0.85 HCRTR1 (0.32) ALDH1A1HTR2CHTR2BCHRM5KDM4E
SCHEMBL6090523 0.85 TNKS2 (0.39) PARP1MEN1KMT2AALDH1A1MAPT
SCHEMBL6089480 0.84 TNKS2 (0.42) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL6091873 0.84 MEN1 (0.42) PARP1MEN1KMT2AALDH1A1GAA
SCHEMBL6089038 0.83 ESR1 (0.36) PARP1PARP2ESR1MEN1KMT2A
SCHEMBL6089041 0.83 ESR1 (0.36) PARP1PARP2ESR1MEN1KMT2A
SCHEMBL6090282 0.82 HTR2C (0.32) MAPTHTR2CHTR2BATMHTR2A
SCHEMBL6089133 0.81 HTR2C (0.36) PARP1ALDH1A1HTR2CHTR2BKDM4E
SCHEMBL6092226 0.81 TNKS2 (0.45) MEN1KMT2AALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 PARP1 1/4885PARP2 2/4885ESR1 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.